Help us create brighter tomorrows.
Clinical Trial Manager (EU) - hubs.ly/Q04FbSX-0
Clinical Trial Manager (EU) - hubs.ly/Q04FbSX-0
Precision for Medicine
@Precision4Med
We help our pharma & life sciences clients innovate, develop, & commercialize next generation medical products.
1.4K Following 1.3K Followers 2.9K Posts
Latest posts 5
When studies change hands, how can progress be preserved and carried forward?
A practical look at how experience, judgment, and adaptability can turn a rescue study into a repeatable operating model: hubs.ly/Q04F5d7s0
A practical look at how experience, judgment, and adaptability can turn a rescue study into a repeatable operating model: hubs.ly/Q04F5d7s0
www.precisionformedicine.com Operational Readiness and Adaptable Project Management Built a Repeatable Early-Phase Oncology... A rescue study reached first patient in within two months, then established repeatable startup, communication and project-management practices for a growing early-phase oncology program. Explore how an IHC-based companion diagnostic for non-muscle invasive bladder cancer moved from recovery mode to clinical trial readiness in roughly six months.
hubs.ly/Q04DS04F0
hubs.ly/Q04DS04F0
www.precisionformedicine.com Case Study: Rapid Execution of Assay Validation Rescued Global Study See how Precision transferred and validated an IHC companion diagnostic under Design Control and supported a performance study application in six months. Learn how a coordinated FSP approach combined focused recruitment, internal screening, blinded candidate profiles, and sponsor meet-and-greet conversations built a multilevel team within 4 months. hubs.ly/Q04DsB540
In this first-in-human oncology study evaluating a RAS-PI3Kα inhibitor, we explore how Precision helped maintain momentum through rapid activation, evolving expansion plans, repeated safety reviews, and shifting development priorities.
hubs.ly/Q04CL5010
hubs.ly/Q04CL5010
www.precisionformedicine.com Case Study: Running an Adaptive Early-Phase RAS Oncology Trial First-in-human Phase I study evaluating a RAS-PI3Kα inhibitor in advanced solid tumors with KRAS, HRAS, or NRAS mutations.